StockData
ADC Therapeutics SA logo

ADC Therapeutics SA (ADCT) stock

ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.37+0.02 (+1.48%)

Close on Nov 18, 2026Market cap $174.90MP/E –Yield –

ADC Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ADC Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$82.93M. For fiscal 2025 it was -$121.50M. The highest annual figure on record is -$119.40M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$121.50M–
FY2024Dec 31, 2024-$130.65M–
FY2023Dec 31, 2023-$165.99M–
FY2022Dec 31, 2022-$123.34M–
FY2021Dec 31, 2021-$261.72M–
FY2020Dec 31, 2020-$219.26M–
FY2019Dec 31, 2019-$119.40M–
FY2018Dec 31, 2018-$125.94M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$14.35M–
Q2 FY2026Jun 30, 2026-$25.41M–
Q1 FY2026Mar 31, 2026-$25.25M–
Q4 FY2025Dec 31, 2025-$17.92M–
Q3 FY2025Sep 30, 2025-$30.97M–
Q2 FY2025Jun 30, 2025-$44.15M–
Q1 FY2025Mar 31, 2025-$28.46M–
Q4 FY2024Dec 31, 2024-$32.44M–
Q3 FY2024Sep 30, 2024-$35.56M–
Q2 FY2024Jun 30, 2024-$29.04M–
Q1 FY2024Mar 31, 2024-$33.61M–
Q4 FY2023Dec 31, 2023-$39.98M–
Q3 FY2023Sep 30, 2023-$36.15M–
Q2 FY2023Jun 30, 2023-$39.65M–
Q1 FY2023Mar 31, 2023-$50.21M–
Q4 FY2022Dec 31, 2022-$10.46M–
Q3 FY2022Sep 30, 2022-$3.11M–
Q2 FY2022Jun 30, 2022-$69.41M–
Q1 FY2022Mar 31, 2022-$40.36M–
Q4 FY2021Dec 31, 2021-$62.78M–
Q3 FY2021Sep 30, 2021-$57.79M–
Q2 FY2021Jun 30, 2021-$70.48M–
Q1 FY2021Mar 31, 2021-$70.67M–
Q4 FY2020Dec 31, 2020-$78.00M–
Q3 FY2020Sep 30, 2020-$52.43M–
Q2 FY2020Jun 30, 2020-$44.95M–
Q1 FY2020Mar 31, 2020-$43.89M–

More ADC Therapeutics figures

See a number that looks wrong?